Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus

Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study

(2023) Michele Correale et al.   ESC Heart Failure

Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction

(2022) Michele Correale et al.   CLINICAL DRUG INVESTIGATION

Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction

(2022) Stefano Ghio et al.   HEART FAILURE REVIEWS

Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis

(2021) Yi-Wen Yu et al.   Cardiovascular Diabetology

Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study

(2021) Jonas Oldgren et al.   DIABETES OBESITY & METABOLISM

Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure

(2021) Michele Correale et al.   CARDIOVASCULAR DRUGS AND THERAPY

Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients

(2021) Michele Correale et al.   HEART FAILURE REVIEWS

Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?

(2021) Michele Correale et al.   HEART FAILURE REVIEWS

Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure

(2020) Hidekazu Tanaka et al.   Cardiovascular Diabetology

Sodium glucose cotransporter‐2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function

(2020) Yi‐Hsin Chan et al.   ESC Heart Failure

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients　― A Randomized Controlled Trial ―

(2020) Hiroyuki Kayano et al.   CIRCULATION JOURNAL

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

(2020) Stefan D. Anker et al.   CIRCULATION

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?

(2019) Carlos G. Santos-Gallego et al.   CARDIOVASCULAR DRUGS AND THERAPY

Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization

(2019) Hana E. Baker et al.   BASIC RESEARCH IN CARDIOLOGY

Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction

(2019) Salva R. Yurista et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients

(2019) Munemitsu Otagaki et al.   CARDIOVASCULAR DRUGS AND THERAPY

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects

(2019) Anastasios Tentolouris et al.   International Journal of Environmental Research and Public Health

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

(2018) Stephen D. Wiviott et al.   AMERICAN HEART JOURNAL

Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction

(2018) Thomas M. Gorter et al.   AMERICAN JOURNAL OF CARDIOLOGY

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

(2016) Naveed Sattar et al.   DIABETOLOGIA

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

(2016) Nikolaus Marx et al.   EUROPEAN HEART JOURNAL

Additional Prognostic Value of EAS index in predicting the occurrence of rehospitalizations in chronic heart failure: data from the Daunia Heart Failure Registry

(2015) Michele Correale et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging

(2015) Jens-Uwe Voigt et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Right Heart Mechanics in Untreated Normotensive Patients with Prediabetes and Type 2 Diabetes Mellitus: A Two- and Three-Dimensional Echocardiographic Study

(2015) Marijana Tadic et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

(2015) Roberto M. Lang et al.   European Heart Journal-Cardiovascular Imaging

Tissue Doppler Time Intervals Predict the Occurrence of Rehospitalization in Chronic Heart Failure: Data from the Daunia Heart Failure Registry

(2012) Michele Correale et al.   ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES